Members of InDex’s senior management were joined by Professor Raja Atreya from the University of Erlangen-Nürnberg and Professor Walter Reinisch from the Medical University of Vienna.
Introduction
Peter Zerhouni, CEO InDex Pharmaceuticals
Ulcerative colitis – a debilitating disease with high unmet medical need
Professor Walter Reinisch, Medical University of Vienna
Cobitolimod – a promising first in class drug candidate for the treatment of ulcerative colitis
Professor Raja Atreya, University of Erlangen-Nürnberg, Principle Investigator in the CONDUCT study
The phase IIb study CONDUCT
Dr Thomas Knittel, Chief Medical Officer InDex Pharmaceuticals
Implementation of the CONDUCT study
Pernilla Sandwall, Chief Operating Officer InDex Pharmaceuticals
Cobitolimod’s market potential
Peter Zerhouni, CEO InDex Pharmaceuticals